The SANBS begins research on Covid-19 treatment
The SANBS intends to start collecting convalescent plasma from donors who have fully recovered from Covid-19
December 2019 will always be remembered as the month when the novel coronavirus disease (Covid-19) started its worldwide spread.
As we sit amid the international pandemic, the SARS-CoV-2 infection continues to claim lives, with the numbers of infections continuing to increase exponentially on a daily basis.
Within the South African context, swift responses have allowed the country to contain a rapid spread of the virus.
The roll-out of a proactive diagnostic programme, isolation and quarantine have all proved effective supportive measures to limit the spread, yet there remains no cure for Covid-19.
There is an international rush to develop vaccines and treatment options for the illness, and effective treatments are crucial for curing patients.
As a cornerstone of the healthcare fraternity in South Africa, the South African National Blood Service (SANBS) and the Western Cape Blood Service (WCBS) are exploring ways to use blood plasma for the treatment of Covid-19 patients locally.
Research forms a large part of their operations, and following the recent approval by their Human Research Ethics Committee they will, in the next few weeks, start collecting convalescent plasma from patients who have recovered from Covid-19.
This convalescent plasma will be used in phase 2 clinical trials to confirm whether this therapy will benefit patients admitted to hospitals with pneumonia caused by the virus. It is noteworthy that the treatment will primarily be in the experimental phase, with the roll-out being a priority.
Convalescent plasma, plasma collected from patients who have recovered from a viral infection, has long been used as a way to treat patients still critically ill from the same viral infection.
This plasma, which contains neutralising antibodies, provides passive immunity to an infected patient, significantly improving their clinical status, often helping them to recover quicker.
It has not been widely used in the South African context yet. Such therapy was explored for patients in West Africa who have contracted the Ebola virus. Before that, it was successfully used to treat SARS-CoV and MERS-CoV.
The development of Covid-19 antibody treatments will, however, take several months to complete.
The SANBS intends to start collecting convalescent plasma from donors who have fully recovered from Covid-19. To be eligible to donate, 28 days must have elapsed since the patients last exhibited symptoms of infection.
This gives the patient time to develop sufficient antibodies to be therapeutic, and to have fully recovered from the disease, which minimises the risk of such patients still being able to transmit the virus. Initially, these plasma products will only be used in patients participating in phase II clinical trials approved by the South African Health Products Regulatory Authority.
While there are still no specific medications approved to treat Covid-19, work has commenced worldwide on convalescent plasma harvested from people who have recovered from the infection.
The SANBS is uniquely positioned to collect and collaborate in clinical trials of convalescent plasma that will subsequently be used in patients hospitalised with Covid-19, in the hope that it will reduce mortality and result in quicker recovery.
*Notice: Coronavirus reporting at Caxton Local Media aims to combat fake news
Dear reader,
As your local news provider, we have the duty of keeping you factually informed on Covid-19 developments. As you may have noticed, mis- and disinformation (also known as “fake news”) is circulating online. Caxton Local Media is determined to filter through the masses of information doing the rounds and to separate truth from untruth in order to keep you adequately informed. Local newsrooms follow a strict pre-publication fact-checking protocol. A national task team has been established to assist in bringing you credible news reports on Covid-19.
Readers with any comments or queries may contact National Group Editor Irma Green (irma@caxton.co.za) or Legal Adviser Helene Eloff (helene@caxton.co.za).
